EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Cell and Gene Therapy Product Approvals in China: Insights into Clinical Trials and Regulatory Advances

Geyun Huang iD, Lijia Xue iD, Li Yang iD

Clinical Pharmacology & Therapeutics · 2025-12 · 118 (6) · 1543-1553

DOI: 10.1002/cpt.70099 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 27.10.2025. Verfasst von Geyun Huang und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China. Hauptthemen laut MEDLINE: Drug Approval, Genetic Therapy, Clinical Trials as Topic, Cell- and Tissue-Based Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Basic Research Project of the Liaoning Provincial Department of Education, Career Development Support Program for Young and Middle-Aged Teachers at Shenyang Pharmaceutical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study undertook a comprehensive analysis to assess China’s progress in the approval of cell and gene therapy products (CGTPs). It provided insights into clinical trials and regulatory advancements by examining the approval characteristics, pivotal clinical trials, expedited programs, orphan designations, development and review timelines, and drug lags through a comparative analysis across four regions: the United States, the European Union, Japan, and China. The findings indicated that China had achieved substantial advancements in the approval of CGTPs in recent years. This progress was evidenced by a year‐over‐year increase in the number of approvals, a flexible authorization approach utilizing surrogate endpoints and single‐arm trials, support for product launches through various expedited programs, and the shortest development timelines among the four regions analyzed. Nevertheless, when compared to the United States, European Union, and Japan, China faced several challenges in the approvals for CGTPs. Notably, the therapeutic area is predominantly in oncology, with the market largely concentrated domestically. Two aspects to be highlighted were that the orphan designation was lacking as well as the implementation of multi‐regional clinical trials (MRCTs) in pivotal clinical trials. Furthermore, the progression of post‐marketing confirmatory trials was sluggish and lacked robust oversight mechanisms. The expedited programs supporting the CGTP approvals required optimization concerning categories and applications. Additionally, the review timelines had not demonstrated a competitive advantage, and the drug lags were the longest across the four regions. It is imperative for regulatory authorities to take proactive measures to mitigate any deficiencies resulting from the identified challenges.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalGenetic TherapyClinical Trials as TopicCell- and Tissue-Based TherapyHumansChinaUnited StatesEuropean UnionJapanOrphan Drug Production

Autor:innen und Institutionen

  • School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China.

ORCID-Profile: Geyun Huang, Lijia Xue, Li Yang

Förderung

  • Basic Research Project of the Liaoning Provincial Department of Education
  • Career Development Support Program for Young and Middle-Aged Teachers at Shenyang Pharmaceutical University

Zitieren

APA

Huang, G., Xue, L., & Yang, L. (2025). Cell and Gene Therapy Product Approvals in China: Insights into Clinical Trials and Regulatory Advances. Clinical Pharmacology & Therapeutics, 118(6), 1543-1553. https://doi.org/10.1002/cpt.70099

Vancouver

Huang G, Xue L, Yang L. Cell and Gene Therapy Product Approvals in China: Insights into Clinical Trials and Regulatory Advances. Clinical Pharmacology & Therapeutics. 2025;118(6):1543-1553. doi:10.1002/cpt.70099

BibTeX
@article{Huang2025,
  author = {Huang, Geyun and Xue, Lijia and Yang, Li},
  title = {Cell and Gene Therapy Product Approvals in China: Insights into Clinical Trials and Regulatory Advances},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {118},
  number = {6},
  pages = {1543--1553},
  doi = {10.1002/cpt.70099}
}
Kostenlos starten →